Decoy Therapeutics Inc. Debt Conversion, Converted Instrument, Amount
Decoy Therapeutics Inc. (DCOY) reported Debt Conversion, Converted Instrument, Amount of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-18.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2021-03-18
- Decoy Therapeutics Inc. debt conversion, converted instrument, amount for the quarter ending 2020-12-31 was $0.00.
- Decoy Therapeutics Inc. debt conversion, converted instrument, amount for the quarter ending 2020-09-30 was $0.00.
- Decoy Therapeutics Inc. debt conversion, converted instrument, amount for the quarter ending 2020-06-30 was $0.00.
- Decoy Therapeutics Inc. debt conversion, converted instrument, amount for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- Decoy Therapeutics Inc. debt conversion, converted instrument, amount for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- Decoy Therapeutics Inc. debt conversion, converted instrument, amount for fiscal 2019 was $2.87M.
- Decoy Therapeutics Inc. debt conversion, converted instrument, amount for fiscal 2018 was $0.00.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $0.00 derived: sum of 2 quarters · filed 2021-03-18 | $0.00 derived: sum of 3 quarters · filed 2021-03-18 | $0.00 10-K · filed 2021-03-18 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 derived: sum of 2 quarters · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | $0.00 derived: sum of 4 quarters · filed 2021-03-18 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2020-08-12 | $0.00 10-Q · filed 2020-08-12 | $0.00 derived: sum of 3 quarters · filed 2021-03-18 | $0.00 derived: sum of 4 quarters · filed 2021-03-18 |
| 2020-03-31 | $0.00 10-Q/A · filed 2020-05-15 | $0.00 derived: sum of 2 quarters · filed 2021-03-18 | $0.00 derived: sum of 3 quarters · filed 2021-03-18 | $0.00 derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $0.00 derived: sum of 2 quarters · filed 2021-03-18 | $0.00 derived: sum of 3 quarters · filed 2021-03-18 | $2.87M 10-K · filed 2021-03-18 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 derived: sum of 2 quarters · filed 2020-11-12 | $2.87M 10-Q · filed 2020-11-12 | $2.87M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2020-08-12 | $2.87M 10-Q · filed 2020-08-12 | $2.87M derived: sum of 3 quarters · filed 2020-08-12 | |
| 2019-03-31 | $2.87M 10-Q/A · filed 2020-05-15 | $2.87M derived: sum of 2 quarters · filed 2020-05-15 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | $0.00 10-K · filed 2020-03-23 | ||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |